Ultrasound-guided delivery of thymidine kinase–nitroreductase dual therapeutic genes by PEGylated-PLGA/PIE nanoparticles for enhanced triple negative breast cancer therapy

What is it about?

Triple negative breast cancer (TNBC) is an aggressive breast cancer phenotype and accounted for about 20% of all breast cancer patients. Combinations of chemotherapies are the only currently recommended treatment options, but the overall response rate is only 16-35% and drug resistance and non-target toxicities are very common. Here we developed gene-directed enzyme prodrug therapy (GDEPT), also called suicide gene therapy, along with efficient nanocarrier (PEG-PLGA/PEI) and gene delivery method (ultrasound-microbubble mediated sonoporation) to improve therapeutic efficiency of TNBC without toxicity.

Featured Image